|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Celgene_Corporation
gptkb:Zymeworks
gptkb:Immunomedics
gptkb:Myokardia
gptkb:Celerion
|
|
gptkbp:CEO
|
Giovanni Caforio
|
|
gptkbp:clinicalTrials
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:drugInterdiction
|
oncology
neuroscience
immunology
virology
cardiovascular
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:John_Myers
gptkb:William_McLaren_Bristol
|
|
gptkbp:headquarters
|
gptkb:New_York
gptkb:New_York_City
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol-Myers Squibb Holdings, Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPeople
|
gptkb:Lamberto_Andreotti
gptkb:Samit_Hirawat
gptkb:Michael_R._Gold
gptkb:Charles_Bancroft
Giovanni Caforio
|
|
gptkbp:numberOfEmployees
|
30,000+
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:NantKwest
gptkb:Pfizer
gptkb:Eli_Lilly_and_Company
AbbVie
|
|
gptkbp:products
|
drugs
|
|
gptkbp:researchAndDevelopment
|
gene therapy
vaccines
biologics
small molecules
cell therapy
|
|
gptkbp:revenue
|
$46.4 billion (2020)
|
|
gptkbp:stockSymbol
|
BMY
|
|
gptkbp:subsidiary
|
gptkb:Bristol-Myers_Squibb_Company
|
|
gptkbp:tradedOn
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:website
|
www.bms.com
|